[1] 侯云德. 重大新发传染病防控策略与效果[J].新发传染病电子杂志,2019,4(3):129-132.
[2] 孙晓冬,王海银.新发传染病流行现状及防治策略[J].上海预防医学,2009,21(9):461-465.
[3] Luke T C,Casadevall A,Watowich S J,et al.Hark back:passive immunotherapy for influenza and other serious infections[J].Crit Care Med,2010,38(4 Suppl):e66-e73.
[4] Marano G,Vaglio S,Pupella S,et al.Convalescent plasma:new evidence for an old therapeutic tool?[J].Blood Transfus,2016,14(2):152-157.
[5] Enria D A,Briggiler A M,Sánchez Z.Treatment of Argentine hemorrhagic fever[J].Antivir Res,2008,78(1):132-139.
[6] Leider J P,Brunker P A R,Ness P M.Convalescent transfusion for pandemic influenza:preparing blood banks for a new plasma product?[J].Transfusion,2010,50(6):1384-1398.
[7] Casadevall A,Dadachova E,Pirofski L A.Passive antibody therapy for infectious diseases[J].Nat Rev Microbiol,2004,2(9):695.
[8] 白文娣,蔡微,陈仕锋,等.以新型冠状病毒肺炎为例浅析血浆疗法的现况及发展[J].病毒学报,2020,36(3):502-507.
[9] Garraud O,Heshmati F,Pozzetto B,et al.Plasma therapy against infectious pathogens,as of yesterday,today and tomorrow[J].Transfus Clinique et Biol,2016,23(1):39-44.
[10] WHO. Ethics of using convalescent whole blood and convalescent plasma during the Ebola epidemic: Interim guidance for ethics review committees, researchers, national health authorities and blood transfusion services[EB/OL]. Geneva: World Health Organization,2015:1-16[2020-04-11]. https://www.who.int/csr/resources/publications/ebola/ethics-convalescent-blood/en/.
[11] Yeh K M,Chiueh T S,Siu L K,et al.Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital[J].J Antimicrob Chemother,2005,56(5):919-922.
[12] Hung I F N,To K K W,Lee C K,et al.Hyperimmune IV immunoglobulin treatment:a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection[J].Chest,2013,144(2):464-473.
[13] Wong H K,Lee C K,Hung I F N,et al.Practical limitations of convalescent plasma collection:a case scenario in pandemic preparation for influenza A (H1N1) infection[J].Transfusion,2010,50(9):1967-1971.
[14] Arabi Y M,Hajeer A H,Luke T,et al.Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection,Saudi Arabia[J].Emerg Infect Dis,2016,22(9):1554-1561.
[15] van Griensven J,Edwards T,de Lamballerie X,et al.Evaluation of convalescent plasma for Ebola virus disease in Guinea[J].N Engl J Med,2016,374(1):33-42.
[16] Cheng Y,Wong R,Soo Y O Y,et al.Use of convalescent plasma therapy in SARS patients in Hong Kong[J].Eur J Clin Microbiol Infect Dis,2005,24(1):44-46.
[17] WHO. Use of Convalescent whole blood or plasma collected from patients recovered from ebola virus disease for transfusion, as an empirical treatment during outbreaks: interim guidance for national health authorities and blood transfusion services[EB/OL]. Geneva: World Health Organization.2014:1-19[2020-04-11].https://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/.
[18] Tedder R S,Samuel D,Dicks S,et al.Detectioncharacterization,and enrollment of donors of Ebola convalescent plasma in Sierra Leone[J].Transfusion,2018,58(5):1289-1298.
[19] Arabi Y,Balkhy H,Hajeer A H,et al.Feasibility,safety,clinical,and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection:a study protocol[J].SpringerPlus,2015,4(1):1-8.
[20] Brown J F,Dye J M,Tozay S,et al.Anti-Ebola virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with Ebola virus disease[J].J Infect Dis,2018,218(4):555-562.
[21] U.S. department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research.Investigational COVID-19 Convalescent Plasma: Guidance for Industry[EB/OL].USA: American Association of Blood Banks,2020:1-12[2020-04-11]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents.
[22] Euproean Commission. An EU programme of COVID-19 convalescent plasma collection and transfusion: Guidance on collection, testing, processing, storage, distribution and monitored use[EB/OL]. EU.2020:1-7[2020-04-11].https://ec.europa.eu/health/blood_tissues_organs/covid-19_en?from=groupmessage&isappinstalled=0.
[23] Brown J F,Rowe K,Zacharias P,et al.Apheresis for collection of Ebola convalescent plasma in Liberia[J].J Clin Apher,2017,32(3):175-181.
[24] Geisen C,Kann G,Strecker T,et al.Pathogen-reduced Ebola virus convalescent plasma:first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies[J].Vox Sang,2016,110(4):329-335.
[25] Chaigne B,Mouthon L.Mechanisms of action of intravenous immunoglobulin[J].Transfus Apher Sci,2017,56(1):45-49.
[26] Burnouf T,Seghatchian J.Ebola virus convalescent blood products:Where we are now and where we may need to go[J].Transfus Apher Sci,2014,51(2):120-125.
[27] Burnouf T.Modern plasma fractionation[J].Transfus Med Rev,2007,21(2):101-117.
[28] Radosevich M,Burnouf T.Intravenous immunoglobulin G:trends in production methods,quality control and quality assurance[J].Vox Sang,2010,98(1):12-28.
[29] Zhang Z,Xie Y W,Hong J L,et al.Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma[J].Transfusion,2005,45(7):1160-1164.
[30] Chun S,Chung C R,Ha Y E,et al.Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with middle east respiratory syndrome[J].Ann Lab Med,2016,36(4):393-395.
[31] Mora-Rillo M,Arsuaga M,Ramírez-Olivencia G,et al.Acute respiratory distress syndrome after convalescent plasma use:treatment of a patient with Ebola virus disease contracted in Madrid,Spain[J].Lancet Respir Med,2015,3(7):554-562.
[32] Mair-Jenkins J,Saavedra-Campos M,Baillie J K,et al.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology:a systematic review and exploratory meta-analysis[J].J Infect Dis,2015,211(1):80-90.
[33] Zhou B P,Zhong N S,Guan Y.Treatment with convalescent plasma for influenza A (H5N1) infection[J].N Engl J Med,2007,357(14):1450-1451.
[34] Hung I F,To K K,Lee C K,et al.Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection[J].Clin Infect Dis,2011,52(4):447-456.
[35] Ko J H,Seok H,Cho S Y,et al.Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection:a single centre experience[J].Antivir Ther,2018,23(7):617-622.
[36] Sullivan H C,Roback J D.Convalescent plasma:therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic[J].Transfus Med Rev,2020,34(3):145-150.
[37] Duan K,Liu B,Li C,et al.Effectiveness of convalescent plasma therapy in severe COVID-19 patients[J].Proc Natl Acad Sci US A,2020,117(17):9490-9496. |
